Catalent (NYSE:CTLT) announced its earnings results on Tuesday. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.03, Morningstar.com reports. The firm had revenue of $725.70 million during the quarter, compared to analysts’ expectations of $719.20 million. Catalent had a return on equity of 15.89% and a net margin of 5.46%. The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.67 earnings per share. Catalent updated its FY 2019 guidance to $1.89-2.06 EPS and its FY20 guidance to ~$1.89-2.06 EPS.

Shares of NYSE CTLT opened at $52.95 on Friday. The business has a fifty day simple moving average of $55.19 and a 200 day simple moving average of $47.74. The company has a current ratio of 2.08, a quick ratio of 1.71 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $7.70 billion, a price-to-earnings ratio of 32.69, a PEG ratio of 2.60 and a beta of 1.64. Catalent has a one year low of $29.23 and a one year high of $58.38.

A number of equities research analysts have issued reports on CTLT shares. Morgan Stanley upped their target price on Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a research report on Wednesday. Zacks Investment Research upgraded Catalent from a “sell” rating to a “hold” rating in a research note on Tuesday. Jefferies Financial Group upgraded Catalent from a “hold” rating to a “buy” rating and upped their target price for the company from $50.00 to $62.00 in a research note on Friday, June 21st. UBS Group upped their target price on Catalent to $64.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Robert W. Baird upped their target price on Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $57.43.

In other Catalent news, insider Barry Littlejohns sold 15,940 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $53.53, for a total transaction of $853,268.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Steven L. Fasman sold 4,053 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $54.04, for a total value of $219,024.12. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in CTLT. Evolution Wealth Advisors LLC acquired a new position in Catalent during the second quarter worth $32,000. Advisory Services Network LLC increased its stake in shares of Catalent by 115.5% in the second quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock valued at $39,000 after buying an additional 395 shares in the last quarter. Bremer Bank National Association acquired a new stake in shares of Catalent in the first quarter valued at $49,000. Zions Bancorporation N.A. acquired a new stake in shares of Catalent in the first quarter valued at $61,000. Finally, Quadrant Capital Group LLC increased its stake in shares of Catalent by 265.0% in the first quarter. Quadrant Capital Group LLC now owns 1,909 shares of the company’s stock valued at $71,000 after buying an additional 1,386 shares in the last quarter. Hedge funds and other institutional investors own 99.94% of the company’s stock.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Story: What are momentum indicators and what do they show?

Earnings History for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.